NCT00600405

Brief Summary

The purpose of this study is to determine the efficacy of the α-adrenergic antagonist tamsulosin in the treatment of adult emergency department (ED) patients with ureteral colic secondary to lower ureteral calculus. We hypothesize that there will be no difference in outcomes for subjects treated with and without tamsulosin.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
81

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2006

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2006

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2007

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

January 14, 2008

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 25, 2008

Completed
Last Updated

January 25, 2008

Status Verified

January 1, 2008

Enrollment Period

1.3 years

First QC Date

January 14, 2008

Last Update Submit

January 14, 2008

Conditions

Keywords

NephrolithiasisUreteral Calculi

Outcome Measures

Primary Outcomes (1)

  • Rate of spontaneous ureteral stone expulsion

    48, 120, 336 hours

Secondary Outcomes (7)

  • Time to spontaneous ureteral stone expulsion.

    48, 120, 336 hours

  • Self-reported NRS-11 pain scores.

    48, 120, 336 hours

  • Number of colicky pain episodes.

    48, 120, 336 hours

  • Number of days missed work or usual functional ability.

    48, 120, 336 hours

  • Number of return ED visits or unscheduled PCP visits for continued pain.

    48, 120, 336 hours

  • +2 more secondary outcomes

Study Arms (2)

I

EXPERIMENTAL

Subjects randomized to the experimental group receive ibuprofen, oxycodone, and tamsulosin 0.4 mg orally daily for ten days.

Drug: tamsulosin

II

OTHER

Standard therapy arm: subjects randomized to standard therapy receive ibuprofen and oxycodone alone.

Drug: Standard therapy with ibuprofen and oxycodone.

Interventions

Tamsulosin 0.4 mg orally daily for ten days.

Also known as: Flomax
I

Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.

II

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older;
  • able to read, write, and speak English;
  • able to use the NRS pain scale; and
  • computed tomography diagnosed single lower ureteral calculus

You may not qualify if:

  • allergy or sensitivity to the study drug (tamsulosin hydrochloride \[Flomax\]);
  • sulfa/sulfonamide allergy;
  • inability to provide informed consent;
  • lithiasis of the ureteral intramural tract;
  • acute or chronic renal failure;
  • fever;
  • presence of multiple ureteral stones;
  • peptic ulcer disease;
  • liver failure;
  • concomitant treatment with alpha-lytic drugs, calcium antagonists, nitrates, or vardenafil (Levitra);
  • pregnancy;
  • breastfeeding; or
  • a history of urinary surgery or endoscopic treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maine Medical Center

Portland, Maine, 04102, United States

Location

MeSH Terms

Conditions

NephrolithiasisUreteral Calculi

Interventions

TamsulosinStandard of CareIbuprofenOxycodone

Condition Hierarchy (Ancestors)

Kidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrolithiasisMale Urogenital DiseasesUreterolithiasisUreteral DiseasesUrinary CalculiCalculiPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

BenzenesulfonamidesSulfonamidesAmidesOrganic ChemicalsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsSulfonesSulfur CompoundsQuality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and EvaluationPhenylpropionatesAcids, CarbocyclicCarboxylic AcidsCodeineMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic Compounds

Study Officials

  • Andrew D Perron, MD

    MaineHealth

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 14, 2008

First Posted

January 25, 2008

Study Start

August 1, 2006

Primary Completion

November 1, 2007

Study Completion

November 1, 2007

Last Updated

January 25, 2008

Record last verified: 2008-01

Locations